Lung Cancer | Specialty

Molecular Testing in Squamous Cell Tumors

July 19th 2016

The Emergence of Liquid Biopsy in Lung Cancer

July 19th 2016

The Importance of Comprehensive Genomic Profiling

July 19th 2016

Lung Cancer Molecular Testing

July 19th 2016

Osimertinib Extends PFS in Phase III Study for T790M-Mutant NSCLC

July 18th 2016

The phase III AURA3 study has confirmed the benefits of osimertinib seen in earlier phase II studies for patients with EGFR T790M-mutant locally-advanced or metastatic non–small cell lung cancer following progression on a frontline EGFR TKI.

Expert Enthusiastic About Immunotherapy in SCLC

July 18th 2016

Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.

Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC

July 14th 2016

Expert Sees Hope for FDA Approvals of BRAF Inhibitors in NSCLC

July 7th 2016

Geoffrey R. Oxnard, MD, discusses the potential for BRAF-targeting therapies in non-small cell lung cancer.

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

July 7th 2016

​Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

BRAF Emerges as Exploitable Target in NSCLC

July 6th 2016

The types of BRAF mutations in non-small cell lung cancer may differ from those observed in melanoma, and a greater understanding of these nuances and their sensitivity to currently available drugs is a central focus of ongoing research.

Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer

July 6th 2016

Dr. Bauer on Rovalpituzumab Tesirine in Patients With SCLC

July 5th 2016

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate in recurrent/refractory patients with small cell lung cancer (SCLC).

Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC

July 4th 2016

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

Dr. Spigel on CheckMate-331 Trial for SCLC

June 29th 2016

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

CHMP Recommends Approval of Pembrolizumab for Lung Cancer

June 28th 2016

The EMA's Committee for Medicinal Products for Human Use has granted a positive opinion for use of pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1-positive non–small cell lung cancer.

Everolimus Survival Benefit Suggested in Updated NET Trial Results

June 23rd 2016

Patients with nonfunctioning neuroendocrine tumors of lung or gastrointestinal origin continued to live longer when treated with the mammalian target of rapamycin inhibitor everolimus (Afinitor) than with placebo.

FDA Approval Sought for Brigatinib in ALK-Positive NSCLC

June 21st 2016

Rolling submission of a new drug application for brigatinib (AP26113) has been initiated for patients with advanced ALK-positive non–small cell lung cancer who are resistant to prior crizotinib (Xalkori).

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

June 18th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Exon 14 Skipping Mutation Could Provide Key to MET Inhibitor Success in Lung Cancer

June 17th 2016

MET exon 14 skipping mutations are emerging as a particularly promising biomarker, at least in the context of lung cancer.

Frontline Pembrolizumab Improves Survival in NSCLC Patients With High PD-L1 Expression

June 17th 2016

Frontline pembrolizumab (Keytruda) improved overall survival versus chemotherapy in non–small cell lung cancer patients with high levels of PD-L1 expression.